Identification
NameBrentuximab vedotin
Accession NumberDB08870
TypeBiotech
GroupsApproved
Description

Brentuximag vedotin or Adcetris® is an antibody-drug conjugate that combines an anti-CD30 antibody and the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Brentuximag vedotin was approved in 2011, and in January 2012, the drug label was revised to include a boxed warning of progressive multifocal leukoencephalopathy and death following JC virus infection.

Protein structureNo structure small
Related Articles
Protein chemical formulaC6476H9930N1690O2030S40
Protein average weight150500.0 Da (range 149200-151800)
SequencesNot Available
Synonyms
cAC10-vcMMAE
External IDs SGN-35
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdcetrisPowder, for solution50 mgIntravenousSeattle Genetics, Inc.2013-02-19Not applicableCanada
AdcetrisInjection, powder, for solution50 mgIntravenousTakeda Pharma A/S2012-10-25Not applicableEu
AdcetrisInjection, powder, lyophilized, for solution50 mg/10.5mLIntravenousSeattle Genetics, Inc.2011-08-25Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII7XL5ISS668
CAS number914088-09-8
Pharmacology
Indication

Used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Structured Indications
Pharmacodynamics

Brentuximag vedotin causes apoptosis of tumor cells by preventing cell cycle progression of the G2 to M phase through disruption of the cytosolic mictrotuble network.

Mechanism of action

Brentuximab vedotin is composed of 3 parts: a chimeric human-murine IgG1 that targets CD30, monomethyl auristatin E (MMAE),which is a microtubule disrupting agent, and a protease-susceptible linker that covalently links the antibody and MMAE. The IgG1 antibody enables brentuximab vedotin to target tumor cells expressing CD30 on their cell surface then brentuximab vedotin gets internalized into the cell. Once inside, the linker is cleaved releasing MMAE which binds disrupts the microtuble network.

TargetKindPharmacological actionActionsOrganismUniProt ID
Tumor necrosis factor receptor superfamily member 8Proteinyes
binder
HumanP28908 details
Related Articles
Absorption

Brentuximab vedotin is administered only as an intravenous infusion so absorption is 100%.

Volume of distribution

The steady state volume of distribution is 6-10 L.

Protein binding

MMAE has a plasma protein binding range of 68-82%, and highly-protein bound drugs are not likely to displace it.

Metabolism

Only a small fraction of MMAE is metabolized primarily via oxidation by CYP3A4 and CYP3A5.

Route of elimination

MMAE is eliminated by the feces (with 72% unchanged) and urine.

Half life

The terminal half-life is 4-6 days.

Clearance

MMAE is cleared by the liver but not quantitative studies have been performed.

Toxicity

The most severe toxic reaction seen in patients is progressive multifocal leukoencephalopathy. Other toxicities include bone marrow suppression, infusion reactions, peripheral neuropathy, Stevens-Johnson syndrome, and tumor lysis syndrome.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetaminophenThe serum concentration of Brentuximab vedotin can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
AfatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Alfentanil.Approved, Illicit
AmantadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amsacrine.Approved
AprepitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Aprepitant.Approved, Investigational
AstemizoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Brentuximab vedotin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Azithromycin.Approved
BelimumabThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Belimumab.Approved
BenzocaineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Brentuximab vedotin.Approved, Investigational
BexaroteneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Brentuximab vedotin can be increased when it is combined with Biperiden.Approved
BleomycinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bleomycin.Approved
BoceprevirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Boceprevir.Approved, Investigational
BortezomibThe metabolism of Brentuximab vedotin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Brentuximab vedotin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Brentuximab vedotin can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ceritinib.Approved
ChloroquineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Brentuximab vedotin can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Brentuximab vedotin can be decreased when combined with Clemastine.Approved
ClofazimineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Brentuximab vedotin.Approved, Investigational
CyclosporineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dactinomycin.Approved
DarunavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Brentuximab vedotin can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Brentuximab vedotin.Approved
DesipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
DesloratadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Brentuximab vedotin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
DigoxinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Brentuximab vedotin can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Brentuximab vedotin.Approved, Investigational
DoxazosinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Brentuximab vedotin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dronedarone.Approved
EfavirenzThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstramustineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fidaxomicin.Approved
FingolimodBrentuximab vedotin may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Brentuximab vedotin can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Brentuximab vedotin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with G17DT.Investigational
GefitinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Glyburide.Approved
Gramicidin DThe serum concentration of Brentuximab vedotin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with INGN 225.Investigational
IsavuconazoniumThe serum concentration of Brentuximab vedotin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Brentuximab vedotin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Leflunomide.Approved, Investigational
LevofloxacinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Lumacaftor.Approved
MaprotilineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Brentuximab vedotin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Brentuximab vedotin can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Methadone.Approved
MetoprololThe serum concentration of Brentuximab vedotin can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Morphine.Approved, Investigational
NafcillinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Brentuximab vedotin can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Norethisterone.Approved
OlaparibThe metabolism of Brentuximab vedotin can be decreased when combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Brentuximab vedotin.Experimental
OmeprazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
P-NitrophenolThe serum concentration of Brentuximab vedotin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paroxetine.Approved, Investigational
PentobarbitalThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Brentuximab vedotin can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Brentuximab vedotin.Approved, Investigational
PimozideThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pimozide.Approved
Platelet Activating FactorThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with CDX-110.Investigational
RitonavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Brentuximab vedotin.Approved
RolapitantThe serum concentration of Brentuximab vedotin can be increased when it is combined with Rolapitant.Approved
SaquinavirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Brentuximab vedotin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Brentuximab vedotin.Approved
SirolimusThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Brentuximab vedotin can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Brentuximab vedotin can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Brentuximab vedotin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Brentuximab vedotin.Approved, Investigational
TacrolimusThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Brentuximab vedotin can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Brentuximab vedotin can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Brentuximab vedotin can be increased when it is combined with Testosterone.Approved, Investigational
TicagrelorThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Brentuximab vedotin can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tocilizumab.Approved
TofacitinibBrentuximab vedotin may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Brentuximab vedotin can be increased when it is combined with Tolvaptan.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Brentuximab vedotin.Approved, Investigational
TrazodoneThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trimipramine.Approved
VenlafaxineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of Brentuximab vedotin can be increased when it is combined with Voriconazole.Approved, Investigational
ZimelidineThe serum concentration of Brentuximab vedotin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Brentuximab vedotin can be decreased when combined with Ziprasidone.Approved
Food InteractionsNo interactions found.
References
Synthesis Reference

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24

General References
  1. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24. [PubMed:12714494 ]
External Links
ATC CodesL01XC12
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (217 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentMalignant Lymphomas1
1Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Leukemia, Lymphoblastic, Acute / Myelodysplastic Syndromes1
1Active Not RecruitingTreatmentLymphoma, Large-Cell, Anaplastic / Lymphoma, NK-cell / T-Cell Lymphomas1
1CompletedTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Hodgkins1
1CompletedTreatmentCarcinoma NOS / Hodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Neoplasms / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentGraft Versus Host Disease (GVHD)1
1CompletedTreatmentHodgkins Disease (HD)1
1CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL)2
1CompletedTreatmentRecurrent Adult Hodgkin's Lymphoma1
1Not Yet RecruitingTreatmentCD30-positive Lymphoma / CD30-positive Solid Tumor1
1Not Yet RecruitingTreatmentHodgkins Disease (HD)1
1RecruitingTreatmentAcute Myelogenous Leukaemia (AML)1
1RecruitingTreatmentClassical Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL)1
1RecruitingTreatmentLymphoma, Hodgkins / Refractory / Relapses1
1RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentMycosis Fungoides (MF) / Sézary Syndrome1
1RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1RecruitingTreatmentRecurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1TerminatedTreatmentGraft Versus Host Disease (GVHD)1
1TerminatedTreatmentHodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentAnaplastic Large Cell Lymphoma / Lymphoma, Hodgkins1
1, 2Active Not RecruitingTreatmentClassical Hodgkin Lymphoma1
1, 2Active Not RecruitingTreatmentHodgkins Disease (HD)1
1, 2Active Not RecruitingTreatmentLymphoma, Hodgkins1
1, 2Active Not RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Refractory Childhood Hodgkin Lymphoma1
1, 2Not Yet RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / Systemic Anaplastic Large Cell Lymphoma1
1, 2RecruitingTreatmentAIDS-Related Hodgkin Lymphoma / CD30-Positive Neoplastic Cells Present / Classical Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Stage II Hodgkin Lymphoma / Stage IIA Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage III Hodgkin Lymphoma / Stage IIIA Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
1, 2RecruitingTreatmentALK+ Anaplastic Large Cell Lymphoma1
1, 2RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Epstein-Barr Virus Infections / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentCD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30 Positive Diffuse Large B-cell Lymphoma or CD30 Positive Grey Zone Lymphoma1
1, 2RecruitingTreatmentClinical Efficacy / Safety1
1, 2RecruitingTreatmentHodgkins Disease (HD)1
1, 2RecruitingTreatmentLymphoma, Hodgkins2
1, 2RecruitingTreatmentNon-Hodgkin's Disease1
1, 2RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma / Refractory Hodgkin Lymphoma1
1, 2TerminatedTreatmentLeukemias1
1, 2WithdrawnTreatmentHematopoietic/Lymphoid Cancer1
1, 2WithdrawnTreatmentLymphoma, Hodgkins / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1
2Active Not RecruitingTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Hodgkins1
2Active Not RecruitingTreatmentCD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma / Cutaneous Lymphomas / Haematological disorders / Malignant Lymphomas / Mycosis Fungoides (MF) / Primary Cutaneous Anaplastic Large Cell Lymphoma / Skin Lymphoma1
2Active Not RecruitingTreatmentFollicular B-cell Non-Hodgkin's Lymphoma / Refractory Diffuse Large B Cell Lymphoma1
2Active Not RecruitingTreatmentGerm Cell Cancer1
2Active Not RecruitingTreatmentHodgkins Disease (HD)1
2Active Not RecruitingTreatmentLymphoma, Hodgkins4
2Active Not RecruitingTreatmentRelapsed/Refractory Hodgkin's Lymphoma1
2Active Not RecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Anemia, Refractory, With Excess of Blasts / Tumors, Solid1
2CompletedTreatmentHodgkins Disease (HD)1
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL) / T-Cell Lymphomas1
2CompletedTreatmentLymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentPrimary mediastinal large B-cell lymphomas1
2CompletedTreatmentRecurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
2Not Yet RecruitingTreatmentAdult T-Cell Leukemia/Lymphoma / Anaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Angioimmunoblastic T-Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified1
2RecruitingTreatmentAdult T-Cell Leukemia/Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Enteropathy Associated T-cell Lymphoma (EATCL) / Hepato-splenic T-cell Lymphoma / NK T-Cell Lymphoma / T-Cell Lymphomas / Transformed Mycosis Fungoides1
2RecruitingTreatmentClassical Hodgkin Lymphoma / Hematopoietic Cell Transplantation Recipient / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
2RecruitingTreatmentClassical Hodgkin Lymphoma / Stage IB Hodgkin Lymphoma / Stage II Hodgkin Lymphoma / Stage IIA Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage III Hodgkin Lymphoma / Stage IIIA Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
2RecruitingTreatmentEmbryonal Carcinoma / Germ Cell Tumors / Neoplasms, Embryonal Germ Cell Tumors / Nonseminomatous Germ Cell Tumor / Testicular Cancer / Testis cancer1
2RecruitingTreatmentGerm Cell Tumors1
2RecruitingTreatmentHIV-associated Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1
2RecruitingTreatmentHodgkins Disease (HD)2
2RecruitingTreatmentHodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic1
2RecruitingTreatmentLung Diseases Due to External Agents / Mesothelioma1
2RecruitingTreatmentLymphatic Diseases2
2RecruitingTreatmentLymphoma, Hodgkins5
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMalignant Lymphomas1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentRecurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
2RecruitingTreatmentRelapsed or Refractory EBV-and CD30-positive Lymphomas1
2RecruitingTreatmentStage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2SuspendedTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma1
2TerminatedTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2Unknown StatusTreatmentLymphoma, Hodgkins1
2WithdrawnSupportive CareGraft Versus Host Disease (GVHD)1
2WithdrawnTreatmentFollicular Lymphoma (FL) / Grey Zone Lymphoma / High Grade B Cell Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Marginal Zone Lymphoma / Mediastinal Large B-cell Lymphoma / Small Lymphocytic Lymphoma (SLL)1
3Active Not RecruitingTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL) / T-Cell Lymphomas1
3Active Not RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL) / Mycosis Fungoides (MF) / Primary Cutaneous Anaplastic Large Cell Lymphoma1
3Active Not RecruitingTreatmentHodgkins Disease (HD)1
3Active Not RecruitingTreatmentLymphoma, Hodgkins1
3Not Yet RecruitingTreatmentHodgkins Disease (HD)1
3RecruitingTreatmentClassical Hodgkin Lymphoma1
3RecruitingTreatmentClassical Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
3RecruitingTreatmentLymphoma, Hodgkins1
4Active Not RecruitingTreatmentAnaplastic Large-Cell Lymphoma1
4Active Not RecruitingTreatmentLymphoma, Hodgkins1
Not AvailableActive Not RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentCutaneous Lymphomas / Cutaneous T Cell Lymphomas (CTCL) / Mycosis Fungoides (MF) / Non-Hodgkin's Lymphoma (NHL) / Sezary Syndrome1
Not AvailableActive Not RecruitingTreatmentHodgkin Lymphoma, Adult1
Not AvailableAvailableNot AvailableHodgkins Disease (HD) / Lymphoma, Large-Cell, Anaplastic / Lymphoma, T-Cell, Cutaneous / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableRecruitingNot AvailableRelapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma1
Not AvailableRecruitingTreatmentLymphoma, Hodgkins1
Not AvailableRecruitingTreatmentMalignant mast cell neoplasm / Systemic Mastocytosis / Systemic mastocytosis with associated hematological neoplasm1
Not AvailableTerminatedTreatmentPeripheral T-Cell Lymphoma (PTCL)1
Not AvailableWithdrawnTreatmentMalignant Lymphomas1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntravenous50 mg
Injection, powder, lyophilized, for solutionIntravenous50 mg/10.5mL
Powder, for solutionIntravenous50 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Tumor necrosis factor-activated receptor activity
Specific Function:
Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B.
Gene Name:
TNFRSF8
Uniprot ID:
P28908
Molecular Weight:
63746.47 Da
References
  1. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24. [PubMed:12714494 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Drug created on May 01, 2013 14:50 / Updated on August 17, 2016 12:24